Advertisement
Screener

Instil Bio, Inc. (TIL) Increase (Decrease) in Prepaid Expense and Other Assets

Instil Bio, Inc. Increase (Decrease) in Prepaid Expense and Other Assets

Instil Bio, Inc. (TIL) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$1.36 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-13

  • Instil Bio, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $162.00K, a 75.15% decline year-over-year.
  • Instil Bio, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was -$1.53M.
  • Instil Bio, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$1.18M.
  • Instil Bio, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $897.00K, a 82.22% decline year-over-year.
  • Instil Bio, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$6.12M, a 2866.97% decline from fiscal 2024.
  • Instil Bio, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $221.00K, a 8.30% decline from fiscal 2023.
  • Instil Bio, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $241.00K, a 43.95% decline from fiscal 2022.
  • Instil Bio, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $430.00K, a 91.48% decline from fiscal 2021.
Period endIncrease (Decrease) in Prepaid Expense and Other Assets 3 monthIncrease (Decrease) in Prepaid Expense and Other Assets 6 monthIncrease (Decrease) in Prepaid Expense and Other Assets 9 monthIncrease (Decrease) in Prepaid Expense and Other Assets 9 month as first filedIncrease (Decrease) in Prepaid Expense and Other Assets 12 month
2026-06-30$162.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
-$1.36M
10-Q · filed 2026-08-13
-$2.55M
derived: sum of 3 quarters · filed 2026-08-13
-$1.65M
derived: sum of 4 quarters · filed 2026-08-13
2026-03-31-$1.53M
10-Q · filed 2026-05-15
-$2.71M
derived: sum of 2 quarters · filed 2026-05-15
-$1.81M
derived: sum of 3 quarters · filed 2026-05-15
-$1.16M
derived: sum of 4 quarters · filed 2026-08-13
2025-12-31-$1.18M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27
-$285.00K
derived: sum of 2 quarters · filed 2026-03-27
$367.00K
derived: sum of 3 quarters · filed 2026-08-13
-$6.12M
10-K · filed 2026-03-27
2025-09-30$897.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
$1.55M
derived: sum of 2 quarters · filed 2026-08-13
-$4.93M
10-Q · filed 2025-11-13
-$7.25M
derived: sum of 4 quarters · filed 2026-08-13
2025-06-30$652.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13
-$5.83M
10-Q · filed 2026-08-13
-$8.15M
derived: sum of 3 quarters · filed 2026-08-13
-$3.10M
derived: sum of 4 quarters · filed 2026-08-13
2025-03-31-$6.48M
10-Q · filed 2026-05-15
-$8.80M
derived: sum of 2 quarters · filed 2026-05-15
-$3.76M
derived: sum of 3 quarters · filed 2026-05-15
-$4.92M
derived: sum of 4 quarters · filed 2026-05-15
2024-12-31-$2.32M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27
$2.73M
derived: sum of 2 quarters · filed 2026-03-27
$1.56M
derived: sum of 3 quarters · filed 2026-03-27
$221.00K
10-K · filed 2026-03-27
2024-09-30$5.04M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13
$3.88M
derived: sum of 2 quarters · filed 2025-11-13
$2.54M
10-Q · filed 2025-11-13
$4.03M
10-Q · filed 2024-11-13
$1.70M
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30-$1.17M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13
-$2.50M
10-Q · filed 2025-08-13
-$3.35M
derived: sum of 3 quarters · filed 2025-08-13
-$3.76M
derived: sum of 4 quarters · filed 2025-08-13
2024-03-31-$1.34M
10-Q · filed 2025-05-13
-$2.18M
derived: sum of 2 quarters · filed 2025-05-13
-$2.60M
derived: sum of 3 quarters · filed 2025-05-13
-$1.87M
derived: sum of 4 quarters · filed 2025-05-13
2023-12-31-$841.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04
-$1.26M
derived: sum of 2 quarters · filed 2025-03-04
-$532.00K
derived: sum of 3 quarters · filed 2025-03-04
$241.00K
10-K · filed 2025-03-04
2023-09-30-$419.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13
$309.00K
derived: sum of 2 quarters · filed 2024-11-13
$1.08M
10-Q · filed 2024-11-13
-$656.00K
derived: sum of 4 quarters · filed 2024-11-13
2023-06-30$728.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13
$1.50M
10-Q · filed 2024-08-13
-$237.00K
derived: sum of 3 quarters · filed 2024-08-13
-$2.68M
derived: sum of 4 quarters · filed 2024-08-13
2023-03-31$773.00K
10-Q · filed 2024-05-10
-$965.00K
derived: sum of 2 quarters · filed 2024-05-10
-$3.40M
derived: sum of 3 quarters · filed 2024-05-10
-$1.62M
derived: sum of 4 quarters · filed 2024-05-10
2022-12-31-$1.74M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21
-$4.18M
derived: sum of 2 quarters · filed 2024-03-21
-$2.40M
derived: sum of 3 quarters · filed 2024-03-21
$430.00K
10-K · filed 2024-03-21
2022-09-30-$2.44M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13
-$657.00K
derived: sum of 2 quarters · filed 2023-11-13
$2.17M
10-Q · filed 2023-11-13
$4.34M
derived: sum of 4 quarters · filed 2023-11-13
2022-06-30$1.78M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14
$4.61M
10-Q · filed 2023-08-14
$6.78M
derived: sum of 3 quarters · filed 2023-08-14
$6.88M
derived: sum of 4 quarters · filed 2023-08-14
2022-03-31$2.83M
10-Q · filed 2023-05-11
$4.99M
derived: sum of 2 quarters · filed 2023-05-11
$5.09M
derived: sum of 3 quarters · filed 2023-05-11
$8.71M
derived: sum of 4 quarters · filed 2023-05-11
2021-12-31$2.17M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31
$2.27M
derived: sum of 2 quarters · filed 2023-03-31
$5.88M
derived: sum of 3 quarters · filed 2023-03-31
$5.04M
10-K · filed 2023-03-31
2021-09-30$99.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14
$3.71M
derived: sum of 2 quarters · filed 2022-11-14
$2.88M
10-Q · filed 2022-11-14
$3.78M
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30$3.61M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12
$2.78M
10-Q · filed 2022-08-12
$3.68M
derived: sum of 3 quarters · filed 2022-08-12
$5.50M
derived: sum of 4 quarters · filed 2022-08-12
2021-03-31-$836.00K
10-Q · filed 2022-05-16
$67.00K
derived: sum of 2 quarters · filed 2022-05-16
$1.89M
derived: sum of 3 quarters · filed 2022-05-16
$1.99M
derived: sum of 4 quarters · filed 2022-05-16
2020-12-31$903.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-07
$2.73M
derived: sum of 2 quarters · filed 2022-03-07
$2.82M
derived: sum of 3 quarters · filed 2022-03-07
$898.00K
10-K · filed 2022-03-07
2020-09-30$1.82M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15
$1.92M
derived: sum of 2 quarters · filed 2021-11-15
-$5.00K
10-Q · filed 2021-11-15
2020-06-30$96.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12
-$1.83M
10-Q · filed 2021-08-12
2020-03-31-$1.92M
10-Q · filed 2021-05-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
Tevogen Inc. (TVGN)United States$0.049B
LeonaBio, Inc. (LONA)United States$0.047B-0.61
Metagenomi Therapeutics, Inc. (MGX)United States$0.044B-0.48
Scilex Holding Co (SCLX)United States$0.042B-0.14
Inmune Bio, Inc. (INMB)United States$0.056B-2.48
ImageneBio, Inc. (IMA)United States$0.056B-1.31
BioAtla, Inc. (BCAB)United States$0.058B-0.21
EXOZYMES INC. (EXOZ)United States$0.058B
MiNK Therapeutics, Inc. (INKT)United States$0.063B-5.37
aTYR PHARMA INC (ATYR)United States$0.033B-0.98